Quantitative Brokers (QB), a leading provider of advanced execution algorithms for institutional traders, has announced the launch of its algorithmic trading suite on B3 – Brasil Bolsa Balcão, Brazil's leading exchange and one of the largest derivatives venues globally.

With this expansion, institutional participants can now access QB's industry-proven execution strategies, engineered for the nuances of local market microstructure to deliver optimal execution quality, directly on B3's futures markets.

QB's core single-leg execution algorithms Bolt, Strobe, and Closer are now available for execution on B3, delivered in partnership with Ideal CTVM, a leader in electronic trading on the exchange since 2019. At launch, clients can deploy these strategies across a range of B3's most actively traded futures contracts, including:

• One-Day Interbank Deposit Futures (DI1)
• Ibovespa Futures (IND)
• Mini Ibovespa Index (WIN)
• USD/BRL Futures (DOL)
• Mini US Dollar Spot (WDO)
• Bitcoin Futures (BIT)
• DI x IPCA Spread (DAP)

Further expansion of both product coverage and available QB strategies on B3 is planned.

"This partnership with B3 and Ideal CTVM allows us to deliver QB's cutting-edge execution strategies on Brazil's leading exchange, while further advancing our growth in Latin America," said David Kalita, CEO of Quantitative Brokers. "Latin America's markets are dynamic and liquid, with rapidly growing demand for advanced tools to control trading costs and manage market impact. This launch marks a key milestone in QB's mission to deliver innovation and measurable value to our clients worldwide."

"Ideal was created with the ambition to modernize the Brazilian trading industry and help drive its growth. Partnering up with an international specialist, to bring state-of-the-art algos for institutional clients is another important step towards that vision. It has been a privilege to work with Quantitative Brokers and key market participants on this project. We are thrilled to help a whole new client base gain access to B3.", said Nilson Monteiro, CEO of Ideal CTVM.